INTRODUCTION

Polycystic ovary syndrome (PCOS) is a common endocrinologic pathology in women of reproductive age with symptoms including menstrual cycle irregularity, hirsutism, hyperandrogenism, and infertility. It is closely related to many clinical conditions such as insulin resistance (IR), hyperinsulinemia, glucose intolerance, dyslipidemia, hypertension, obesity, hyperandrogenism, endothelial dysfunction, and chronic low-grade inflammation. White blood cell subtype ratios are important in identifying low-grade inflammation, and neutrophil-to-lymphocyte ratios (NLR), platelet-to-lymphocyte ratios (PLR), and lymphocyte-to-monocyte ratios (LMR) are used to evaluate the prognosis in some diseases. Chronic low-grade inflammation is also known to have a stimulatory effect on the development of endothelial disease and atherosclerosis.

High-density lipoproteins (HDL) play a role in reducing atherosclerosis and cardiovascular complications. Markers such as total cholesterol (TC)/HDL, low-density lipoprotein (LDL)/HDL, and triglycerides (TG)/HDL can provide information about long-term PCOS complications.

The study compared hormone profiles, lipid profiles, and inflammatory parameters of PCOS patients with those of non-PCOS patients and examined predictive markers in young PCOS patients who have not yet had children.

METHODS

A total of 46 women with the diagnosis of PCOS and 41 healthy women who applied to the Tokat Gaziosmanpaşa University Research and Application Hospital Gynecology and Obstetrics...
Clinic were included in the study. Informed consent was obtained from all participants. Approval was obtained from the Faculty Ethics Committee before the start of the study (dated: October 15, 2020, project number: 20-KAEK-263).

The Rotterdam criteria (clinical or biochemical hyperandrogenism, anovulation or oligomenorrhea, and sonographically polycystic appearance of the ovaries) were used to diagnose PCOS, and if at least two of the three major criteria were present, the diagnosis was made. The presence of hirsutism, which is one of the findings of hyperandrogenism, was also evaluated using the Ferriman-Gallwey scoring system and score above 8 was considered hyperandrogenism. The patients’ age, height, weight, body mass index (BMI), waist circumference (WC), degree of hirsutism, and ultrasonographic findings were recorded. The examinations, pelvic ultrasound, and peripheral venous blood sampling of the participants were performed between days 2 and 4 of the menstrual cycle. All women underwent transabdominal pelvic ultrasonography with a 1.4–5 MHz (GE Logiq P5, GE Healthcare, USA) 4C Convex probe by the same gynecologist. A regularly maintained device (Mindray BC-6800, China) was used for complete blood count. A regularly maintained Roche Cobas e601 (Roche Diagnostics GmbH, Germany) device was used for other tests. The parameters of complete blood count, follicle-stimulating hormone (FSH), luteinizing hormone (LH), serum estradiol (E2), thyroid stimulating hormone (TSH), free thyroxine (T4), prolactin, total testosterone, DHEA-SO4, glucose, insulin, TC, TG, LDL, cholesterol, and HDL cholesterol levels were measured. A HOMA-IR (fasting blood glucose mg/dL × fasting insulin mIU/L/405) value of ≥2.5 was considered the presence of IR. TC/HDL, TG/HDL, LDL/HDL, NLR, monocyte/high-density lipoprotein (MHR), monocyte/PLT, PLT/lymphocyte ratio (PLR), LMR, and systemic immune-inflammation index (SII/SIRS) parameters (NLR×PLT; NLR/PLR) were also calculated. Patients with chronic diseases (e.g., congenital adrenal hyperplasia, Cushing’s syndrome, and androgen-secreting tumors), taking medications (diabetic, antihypertensive, antilipidemic, oral contraceptives), who gave birth, and who had a history of surgery were excluded from the study.

Power analysis was performed using G-Power 3.1.9.7. It was found that at least 64 subjects were required, with an effect size of 0.80, a margin of error of 0.05, and a power of 0.80 (80%). The SPSS (Statistical Package for Social Sciences) program for Windows 22.0 (IBM SPSS, USA) was used for statistical analysis. The statistical methods used were the t-test for the variables with a normal distribution, the significance test for the difference between two means, and the Mann-Whitney U test for the variables that did not have a normal distribution. The chi-square test was used for the comparison of categorical variables. A Pearson’s correlation analysis was performed to determine the relationship between variables. The statistical significance level was accepted as p<0.05.

RESULTS

The demographic characteristics of the cases are shown in Table 1. A statistically significant difference was found between the values of height, weight, BMI, WC, and hirsutism scores of the groups (p<0.05) (Table 1).

The results of hormone profiles and biochemical parameters of PCOS patients and control group are shown in Table 2. Although fasting glucose level was similar between the groups (p=0.946), insulin and IR levels calculated using HOMA-IR were significantly higher (p=0.001) in the PCOS patients (Table 2). IR defined as HOMA-IR ≥2.1 was present in 41 (63.1%) patients with PCOS. The Pearson’s correlation analysis of the PCOS group revealed a negative correlation between

| Hormonal parameters | PCOS (n=41)(mean±SD) | Control (n=46)(mean±SD) | p  |
|---------------------|----------------------|-------------------------|----|
| Age (years)         | 22.5±1.58            | 22.6±1.63               | 0.930* |
| Height (m)          | 1.62±0.55            | 1.65±0.56               | 0.048* |
| Weight (kg)         | 63.1±7.29            | 58.8±9.87               | 0.001* |
| BMI (kg/m²)         | 23.8±2.69            | 21.5±3.46               | 0.001* |
| WC (cm)             | 81.5±8.59            | 76.4±8.34               | 0.005* |
| Hirsutism score     |                      |                         |    |
| Mild (%)            | 17 (28.3)            | 43 (71.7)               | 0.001* |
| Moderate (%)        | 24 (88.9)            | 3 (11.1)                |    |

PCOS: polycystic ovary syndrome; BMI: body mass index; WC: waist circumference. Bold indicates statistical significance: *p<0.05. †Mann-Whitney U test for continuous variables. ‡Pairwise t-test for continuous variables. χ² for categorical variables. Data were given as mean±standard deviation or number (%).
T4 and weight, BMI, and WC (r=-0.421, p=0.004; r=-0.374, p=0.010; r=-0.389, p=0.008, respectively). When comparing the SIRS parameters (NLR×PLT; NLR/PLR) between the control and PCOS groups, no statistically significant differences were found (p=0.185; p=0.580).

HDL cholesterol levels were found to be statistically significantly lower in the PCOS group (p=0.001). The PCOS group had hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, and statistically higher ratios of TC/HDL, LDL/HDL, and TG/HDL (Table 2). The Pearson’s correlation analysis showed a positive correlation between the TC/HDL ratio and the parameters TG/HDL, LDL/HDL, insulin, HOMA-IR, LDL, and triglycerides in the patients of the PCOS group (Table 3). When monocyte/HDL ratios were evaluated, a positive correlation between monocyte, TC/HDL, TG/HDL, LDL/HDL, and TG levels was found in the Pearson’s correlation (Table 3).

Table 2. Comparison of hormonal and biochemical parameters between the study and control group.

| Hormonal parameters | PCOS (n=41)(mean±SD) | Control (n=46)(mean±SD) | p-value |
|---------------------|---------------------|-------------------------|---------|
| FSH (mIU/mL)        | 5.46±0.96           | 5.87±1.00               | 0.055^a|
| LH (mIU/mL)         | 9.88±6.47           | 5.49±2.02               | 0.001^a|
| E2 (pg/mL)          | 47.13±30.54         | 40.05±12.59             | 0.153^a|
| Total testosterone (ng/dL) | 0.43±0.19       | 0.31±0.21               | 0.007*b|
| Prolactin (ng/mL)   | 21.43±9.30          | 18.97±8.82              | 0.210^b|
| DHEA-SO₄ (μg/dL)    | 316.81±118.98       | 262.37±62.77            | 0.011^b|
| Insulin (μIU/mL)    | 20.29±3.84          | 11.93±10.79             | 0.001^b|
| HOMA-IR             | 4.51±0.96           | 2.70±2.66               | 0.001^b|
| HOMA-IR >2.1 (%)    | 41 (63.1)           | 24 (36.9)               | 0.001^c|
| TSH (μIU/L)         | 1.60±0.68           | 1.80±0.96               | 0.272^b|
| T4 (μg/dL)          | 1.27±0.19           | 1.28±0.16               | 0.817^b|
| Biochemical parameters |                      |                        |         |
| Glucose (mg/dL)     | 89.87±7.26          | 89.77±6.18              | 0.946^a|
| Triglyceride (mg/dL)| 81.24±29.84         | 74.60±30.45             | 0.307^a|
| Total cholesterol (mg/dL) | 157.05±20.92   | 158.67±29.02             | 0.764^a|
| HDL cholesterol (mg/dL) | 49.66±9.25     | 61.33±13.82              | 0.001^b|
| LDL cholesterol (mg/dL) | 91.15±19.25   | 91.83±23.62              | 0.884^a|
| WBC (10⁹/mL)        | 7.67±1.70          | 7.77±1.88               | 0.806^a|
| Neutrophils (10³/mL)| 4.78±1.48          | 4.59±1.27               | 0.521^a|
| Lymphocytes (10³/mL)| 2.33±1.58          | 2.17±0.51               | 0.522^a|
| PLT (10³/mL)        | 313.27±76.56       | 289.01±70.02             | 0.126^a|
| Hemoglobin (g/dL)   | 13.42±1.02         | 13.12±1.15              | 0.218^a|
| Monocyte (10³/mL)   | 598.54±178.54      | 683.04±213.12            | 0.049^a|
| MPV                 | 9.12±1.27          | 9.39±1.14               | 0.292^a|
| Neutrophil/lymphocyte ratio | 2.34±1.01  | 2.18±0.67              | 0.367^a|
| PLT/lymphocyte ratio | 151.45±47.79  | 138.49±42.78            | 0.185^a|
| MHR                 | 12.68±4.96         | 11.56±3.99              | 0.249^a|
| Total cholesterol/HDL | 3.25±0.68      | 2.66±0.56               | 0.001^b|
| Monocyte/PLT        | 0.002±0.000        | 0.0025±0.001            | 0.052^a|
| Lymphocytes/monocyte | 4.38±4.07      | 3.42±1.23              | 0.171^a|
| LDL/HDL ratio       | 1.90±0.56          | 1.57±0.50               | 0.004^b|
| TG/HDL ratio        | 1.74±0.90          | 1.31±0.68               | 0.011^b|

PCOS: polycystic ovary syndrome; FSH: follicle-stimulating hormone; LH: luteinizing hormone; E2: estradiol; DHEA-SO₄: dehydroepiandrosterone sulfate; HOMA-IR: homeostatic model assessment insulin resistance; TSH: thyroid-stimulating hormone; T4: thyroxine; 25OHD: 25-hydroxy vitamin D; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglyceride; WBC: white blood cells; PLT: platelet; MPV: mean platelet volume; MHR: monocyte/high-density lipoprotein ratio. *Mann-Whitney U test for continuous variables. **Pairwise t-test for continuous variables. χ² test for categorical variables. Data were given as mean±standard deviation or number (%). Bold indicates statistical significance: p<0.05.
DISCUSSION

PCOS is a common disease at reproductive age and it negatively affects women’s health with its long-term effects. It can cause diseases such as coronary heart disease, impaired glucose tolerance, type 2 diabetes, endometrial cancer, and breast cancer7. PCOS is also associated with increased oxidative stress and low-grade chronic inflammation (CI)8. CI affects the clinical findings and complications of PCOS9. It is already known that IR is associated with low-grade CI. Hyperandrogenism and IR are common findings in women with PCOS8. In this study, the values for weight, BMI, WC, IR, and hirsutism scores were higher in the PCOS group than those in the control group, which is consistent with the literature data.

HDL cholesterol has anti-inflammatory, antioxidant, and antithrombotic effects9. Monocyte/HDL is a marker that has previously been associated with cardiovascular events10. In a study on 61 PCOS patients conducted by Usta et al, monocyte/HDL was found to be a useful marker for diagnosing PCOS and predicting cardiovascular complications11. Another study reported that the monocyte/HDL ratio was significantly higher in PCOS patients compared with the control group12. In contrast to reports in the literature, no significant differences in monocyte/HDL were found between the PCOS and control groups in this study. The measurement of ApoA/ApoB, which is one of the best known atherogenic and thus cardiovascular disease risk indicators, is the most studied13. The ratio of TC/HDL or LDL/HDL is the surrogate for ApoB/ApoA14. In a study of 99 PCOS patients conducted by Cakir and Simsek, the ratio of TC/HDL was significantly higher9. In this study, the ratios of TC/HDL and LDL/HDL were significantly higher in the PCOS group than those in the control group. It has been shown that the TG/HDL ratio can be used to define insulin-resistant individuals15. In this study, the TG/HDL ratio was found to be significantly higher in the PCOS group than that in the control group. This result was similar to the literature.

NLR is a peripheral blood marker associated with inflammation and has been used in many studies as a potential biomarker to reflect the inflammatory status of the body and evaluate disease prognosis16. Yılmaz et al. found that NLR was higher in the PCOS group than that in the control group17. Another study reported that NLR was significantly higher9. In this study, no significant differences were found for NLR between the PCOS and control groups. The greater the platelet volume, the easier the release of inflammatory factors. Based on this information, some studies have found that PLR and MPV can be used as markers to detect inflammation18. In a study of 48 PCOS patients, Kebapcilar et al. reported that WBC and MPV values were higher in the PCOS group than those in the group without PCOS19. In another study, MPV was found to be higher in the PCOS group than that in the control group17. In this study, no significant differences were found between the PCOS and control groups in terms of MPV values. SII/SIRS is defined as NLR×platelets and is another effective indicator of inflammatory status that has been widely used to predict disease prognosis in recent studies20. In a case-control study with 527 participants, it was found that patients with PCOS had higher NLR, PLR, and SII ratios than those in the control group, which indicated that PCOS patients were in an inflammatory state18. In this study, there was no difference in SII values between groups, which was due to the small number of patients in the study. The fact that the monocyte/HDL, NLR, MPV, and SII/SIRS values in our study were similar in the PCOS and control groups, in contrast to the literature, is probably because the patient population was young and had not given birth to children, and the number of patients was small. The limitations of this study were the relatively small number

Table 3. The Pearson correlation results between the hormone values, hemogram, and blood lipid ratios of the polycystic ovary syndrome group.

|                | TG/HDL   | LDL/HDL   | MPV      | NLR/PLR  |
|----------------|----------|-----------|----------|----------|
| r              | p        | r         | p        | r        | p        | R        | p        |
| BMI            | -0.034   | 0.833     | -0.127   | 0.429    | -0.243   | 0.126    | 0.171    | 0.286    |
| Insulin        | 0.303    | 0.054     | 0.302    | 0.055    | -0.249   | 0.117    | -0.121   | 0.449    |
| HOMA-IR        | 0.433    | **0.005** | 0.326    | **0.037**| -0.254   | 0.109    | -0.092   | 0.565    |
| DEAS-SO₄      | -0.084   | 0.603     | -0.089   | 0.579    | -0.173   | 0.280    | -0.014   | 0.929    |
| FSH            | 0.058    | 0.720     | -0.103   | 0.524    | -0.297   | 0.059    | 0.100    | 0.534    |
| LH             | -0.147   | 0.358     | -0.237   | 0.136    | 0.261    | 0.099    | -0.051   | 0.752    |
| Testosterone   | -0.197   | 0.218     | -0.212   | 0.184    | -0.207   | 0.194    | -0.086   | 0.594    |

BMI: body mass index; HOMA-IR: homeostatic model assessment insulin resistance; HDL: high-density lipoprotein; LDL: low-density lipoprotein; TG: triglyceride; FSH: follicle-stimulating hormone; LH: luteinizing hormone; DHEA-SO₄: dehydroepiandrosterone sulfate; MPV: mean platelet volume; PLR: platelet lymphocyte ratio; NLR: neutrophil/lymphocyte ratio. Bold indicates statistical significance: p<0.05.
of patients and the retrospective design. The strength of the study was the hematologic parameters and lipid parameters were presented together in the same study.

CONCLUSIONS

PCOS patients are at risk of short- and long-term complications, and the practical use of the TC/HDL, LDL/HDL, and TG/HDL ratios in the follow-up of these patients may allow for easy patient follow-up. The health status of PCOS patients can be objectively determined by monitoring these results at regular intervals. Prospective studies with a large number of participants need to be conducted to obtain clearer results.

REFERENCES

1. Yildiz BO, Bozdag G, Yapici Z, Esiner I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067-73. https://doi.org/10.1093/humrep/des232
2. Yayla C, Abkoba MK, Gayretli Yayla K, Ertim AG, Efe TH, Sen F, et al. A novel marker of inflammation in patients with slow coronary flow: lymphocyte-to-monocyte ratio. Biomark Med. 2016;10(5):485-93. https://doi.org/10.2217/bmm-2016-0022
3. Fauser BC, Tlaratzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38. e25. https://doi.org/10.1016/j.fertnstert.2011.09.024
4. Garzia E, Galiano V, Marfa G, Navone S, Grossi E, Marconi AM. Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients. Reprod Biol Endocrinol. 2022;20(1):6. https://doi.org/10.1186/s12958-021-00876-0
5. Eslamian G, Hekmatdoost A. Nutrient patterns and risk of polycystic ovary syndrome. J Reprod Infertil. 2019;20(3):161-8. PMID: 31423419
6. Szczuko M, Hawrylukovicz V, Kikut J, Drozd A. The implications of vitamin content in the plasma in reference to the parameters of carbohydrate metabolism and hormone and lipid profiles in PCOS. J Steroid Biochem Mol Biol. 2020;198:105570. https://doi.org/10.1016/j.jsbmb.2019.105570
7. Rudnicka A, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789. https://doi.org/10.3390/ijms22073789
8. Ebejer K, Calleja-Agius J. The role of cytokines in polycystic ovarian syndrome. Gynecol Endocrinol. 2013;29(6):536-40. https://doi.org/10.3109/09513590.2012.760195
9. Çakir I, Simsek Y. Total cholesterol/HDL cholesterol ratio and monocyte/HDL cholesterol ratio are related with subclinical hypercoagulability in polycystic ovary syndrome. Turk J Biochem. 2021;47(1):1-5. https://doi.org/10.1515/tjb-2021-0050
10. Vahit D, Abkoba MK, Samey T, Hüseyin E. Assessment of monocyte to high density lipoprotein cholesterol ratio and lymphocyte-monocyte ratio in patients with metabolic syndrome. Biomark Med. 2017;11(7):535-40. https://doi.org/10.2217/bmm-2016-0380
11. Usta A, Avci E, Bulbul CB, Kadi H, Adali E. The monocyte counts to HDL cholesterol ratio in obese and lean patients with polycystic ovary syndrome. Reprod Biol Endocrinol. 2018;16(1):34. https://doi.org/10.1186/s12958-018-0351-0
12. Herikloğlu D, Gökçen S. Correlation of monocyte/HDL ratio (MHR) with inflammatory parameters in obese patients diagnosed with polycystic ovary syndrome. Ginekologia polska. 2021;92(8):537-43. https://doi.org/10.5603/GPa.2020.0191
13. Yusuf S, Hawken S, Quanpuu S, Dans T, Avezum A, Lanas F, et al. Investigators IS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. https://doi.org/10.1016/S0140-6736(04)17018-9
14. Wild RA. Dyslipidemia in PCOS. Steroids. 2012;77(4):295-9. https://doi.org/10.1016/j.steroids.2011.12.002
15. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003;139(10):802-9. https://doi.org/10.7326/0003-4819-139-10-200311180-00007
16. Fest J, Ruiter TR, Koerkamp BG, Rizopoulos D, Ikram MA, van Eijck CH, et al. The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study, Eur J Epidemiol. 2019;34(5):463-70. https://doi.org/10.1007/s10654-018-0472-y
17. Yilmaz MA, Duran C, Basaran M. The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome. J Endocrinol Invest. 2016;39(1):45-53. https://doi.org/10.1007/s40618-015-0335-2
18. Wang Q, Sun Y, Xu Q, Liu W, Wang P, Yao J, et al. Higher dietary inflammation potential and certain dietary patterns are associated with polycystic ovary syndrome risk in China: a case–control study. Nutr Res. 2022;100:1-18. https://doi.org/10.1016/j.nutres.2021.12.006
19. Kebapcilar L, Taner CE, Kebapcilar AG, Sari I. The mean platelet volume and low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280(2):187-93. https://doi.org/10.1007/s00404-008-0884-0
20. Nast TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Eur J Epidemiol. 2021;36(8):841-8. https://doi.org/10.1007/s10654-021-00752-6